<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949598</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000638373</org_study_id>
    <nct_id>NCT00949598</nct_id>
  </id_info>
  <brief_title>Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer</brief_title>
  <official_title>Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      letrozole may fight breast cancer by blocking the uptake of estrogen. Tamoxifen citrate may&#xD;
      fight breast cancer by blocking the use of estrogen by the tumor cells. It is not yet known&#xD;
      whether letrozole or tamoxifen citrate is more effective when given before surgery in&#xD;
      treating older women with breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying letrozole to see how well it works&#xD;
      compared with tamoxifen citrate in treating older postmenopausal women undergoing surgery for&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Investigate the changes in Ki67 and PCNA in postmenopausal women with estrogen&#xD;
           receptor-positive (ER+) breast cancer after 4 months of treatment with letrozole vs&#xD;
           tamoxifen citrate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the response after 4 months of therapy.&#xD;
&#xD;
        -  Define the resistant forms of cancer in patients treated with these regimens.&#xD;
&#xD;
        -  Define the molecular signature predictive of sensitivity or resistance to ER+ breast&#xD;
           adenocarcinoma by gene and serum protein profiling.&#xD;
&#xD;
        -  Search for serum protein profiles predictive of recurrence-free interval.&#xD;
&#xD;
      OUTLINE: Patients are randomized into 1 of 2 intervention arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral letrozole once daily for 16 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive oral tamoxifen citrate once daily for 16 weeks. Patients in&#xD;
           both arms then undergo surgery.&#xD;
&#xD;
      Blood and tumor tissue samples are collected at baseline and after completion of neoadjuvant&#xD;
      therapy for changes in Ki67 and PCNA and serum protein profiling analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 6 months for 3 years, and&#xD;
      then once a year for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Ki67 and PCNA after 4 months of treatment with letrozole vs tamoxifen citrate</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular signature predictive of sensitivity or resistance to estrogen receptor-positive breast adenocarcinoma</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral letrozole once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral tamoxifen citrate once daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast adenocarcinoma&#xD;
&#xD;
               -  Clinically T2 tumor and/or &gt; 1 cm by echography&#xD;
&#xD;
               -  Estrogen receptor (ER)-positive and &gt; 10% of the tumor cells positive&#xD;
&#xD;
                    -  No ER-negative disease&#xD;
&#xD;
          -  No prior breast cancer&#xD;
&#xD;
          -  No metastatic or inflammatory breast adenocarcinoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  No cardiac function that could contraindicate surgery or medical treatment (e.g.,&#xD;
             radiotherapy and/or chemotherapy)&#xD;
&#xD;
          -  No prior malignancies within the past 5 years except for nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No mental incapacitation that would preclude consent&#xD;
&#xD;
          -  No contraindication to tamoxifen citrate or letrozole&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 8 days since prior hormone-replacement therapy or other treatment (i.e.,&#xD;
             phytoestrogen) for menopause&#xD;
&#xD;
          -  No concurrent therapy that would modify the expression of the genes regulated by&#xD;
             estrogen&#xD;
&#xD;
          -  No concurrent participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Rouanet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

